Chaga grows as a distinctive, dark, charcoal-like growth on birch trees across cold Northern forests, particularly Siberia, where it has been used in folk medicine for centuries, often brewed as a tea substitute in regions where conventional tea was scarce or expensive. Russian and Baltic folk traditions documented its use for general vitality and digestive complaints, and it entered more formal Russian medical use by at least the 16th century.
Chaga's modern Western popularity has grown substantially as part of the broader medicinal mushroom trend, often marketed alongside claims about cancer, immunity, and antioxidant "superfood" status that run well ahead of what human research has actually established.
Chaga has an unusually thin human evidence base even by the standards of the "Limited" category. A comprehensive evidence review found that roughly 70% of all Chaga research occurs in test tubes on isolated cells, and identified only one study involving actual human participants — with zero human clinical trials existing for the cancer, diabetes, or immune claims most commonly attached to chaga in marketing. Memorial Sloan Kettering Cancer Center's integrative medicine database states plainly that chaga's "safety and efficacy have yet to be evaluated in clinical studies."
One small human study — 8 weeks, examining immune cell activity — did find some positive markers, but this remains essentially the sole human data point supporting chaga's immune claims. A genuine and important safety concern worth flagging: chaga contains unusually high oxalate levels, and a documented case report describes a patient developing oxalate nephropathy (kidney damage) after chaga consumption. Given an almost entirely laboratory-based evidence foundation and a real, documented safety concern, "Limited" is the accurate, safety-conscious rating.
Traditionally brewed as a tea from the dried, ground fungal growth, often steeped for extended periods; also prepared as tinctures.